Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -59,695 | -40,759 | -23,258 | -60,925 | -35,939 |
| Depreciation Amortization | 570 | 379 | 189 | 750 | 861 |
| Accounts payable and accrued liabilities | -1,656 | -2,567 | 4,824 | 564 | -1,041 |
| Other Working Capital | -13,981 | -10,083 | -1,880 | 6,779 | 78 |
| Other Operating Activity | 5,273 | 4,805 | -3,204 | 2,812 | 3,388 |
| Operating Cash Flow | $-69,489 | $-48,225 | $-23,329 | $-50,020 | $-32,653 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 50,355 | 46,355 | 27,855 | 29,844 | 33,814 |
| PPE Investments | -145 | -94 | -79 | -314 | -185 |
| Investing Cash Flow | $50,210 | $46,261 | $27,776 | $29,530 | $33,629 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 64,567 | 17,495 | 9,955 | 16,298 | 10,699 |
| Other Financing Activity | 50,224 | 20,081 | 20,231 | -158 | -158 |
| Financing Cash Flow | $114,791 | $37,576 | $30,186 | $16,140 | $10,541 |
| Beginning Cash Position | 29,730 | 29,730 | 29,730 | 34,080 | 34,080 |
| End Cash Position | 125,242 | 65,342 | 64,363 | 29,730 | 45,597 |
| Net Cash Flow | $95,512 | $35,612 | $34,633 | $-4,350 | $11,517 |
| Free Cash Flow | |||||
| Operating Cash Flow | -69,489 | -48,225 | -23,329 | -50,020 | -32,653 |
| Capital Expenditure | -145 | -94 | -79 | -314 | -185 |
| Free Cash Flow | -69,634 | -48,319 | -23,408 | -50,334 | -32,838 |